Aquestive Therapeutics (AQST) Stock Price, Quote, News & History | Benzinga

SPY—QQQ—BTC/USD—DIA—GLD—TLT—

Aquestive Therapeutics Inc (AQST) Stock Price, Quote, News & History

AQSTNASDAQ

Trade with Public

Trade with Public

$3.78

-0.28-6.9%

Last update: Oct 16, 7:59 PM

$3.88

-0.18-4.43%

OverviewNews Earnings Forecast Events Price Targets Financials Sentiment Ownership Compare Options Stock Report

Key Statistics

Open

-

Close

$3.78

Volume / Avg.

16.00 / 2.68M

Day Range

- - -

52 Wk Range

2.93 - 7.55

Market Cap

$486.99M

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

29

Short Interest

23.98%

Days to Cover

13.06

Recent Aquestive Therapeutics, Inc. News

Eton Pharmaceuticals Lands Exclusive US Rights To Aquestive's Seizure Rescue Drug

Eton Pharmaceuticals licenses Aquestive’s LIBERVANT buccal film for U.S. seizure cluster treatment, with launch set for April 2027.

Vandana Singh

Aquestive Therapeutics Resubmits FDA Application for Pocket-Sized Allergy Treatment

Aquestive Therapeutics has resubmitted its New Drug Application to the FDA for Anaphylm, a sublingual film for severe allergic reactions.

Vandana Singh

Aquestive Prepares FDA Resubmission for Severe Allergy Treatment Following Successful Study

Aquestive Therapeutics reports positive study results for Anaphylm sublingual film, paving the way for a Q3 FDA resubmission.

Vandana Singh

Varex Imaging Posts Upbeat Q3 Earnings, Joins Bowman Consulting, MarineMax And Other Big Stocks Moving Higher On Monday

BWMN gained 55.1%, HZO rose 45.8%, ABCL gained 35.6%, SLN rose 34.3%, ACHR gained 19.5%, NESR gained 16.4%, AQST gained 15.4%, STDN rose 13.7%.

Avi Kapoor

Staar Surgical Posts Upbeat Q1 Results, Joins Cisco, Yeti Holdings And Other Big Stocks Moving Higher On Thursday

U.S. stocks rose, with Dow Jones up 300 points. STAA shares surged after better-than-expected results. Other big gainers include POET, STUB, MSC, ARX, CSCO, PCT, WOLF, CPA, ONDS, KLAR, and RDW.

Avi Kapoor

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

-45.37M

Investing Cash Flow (TTM)

-584.00K

Financing Cash Flow (TTM)

83.90M

Free Cash Flow (TTM)

-45.95M

Capital Expenditure (TTM)

-584.00K

Net Change in Cash (TTM)

37.95M

Analyst Trends and Forecast

1

Aug

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

4.5

Strong Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$434.35M

PE Ratio (TTM)

-

PE Ratio (FWD)

-

PEG Ratio (TTM)

-

PS Ratio (TTM)

8.38

PB Ratio (TTM)

-

Earnings Yield % (TTM)

-17.48%

Earnings Yield % (FWD)

-13.51%

EV / EBITDA (TTM)

-

Price / EBITDA (TTM)

-

Price / Free Cash Flow (TTM)

-

Book Value / Share

-$0.45

Company Debt

Total Debt

$50.69M

LT Debt

$50.65M

LT Debt Issuance (TTM)

-

LT Debt Repayment (TTM)

-$48.92M

Total Cash

$98.49M

Debt to Equity

-

Issuance of Debt (TTM)

$5.42M

Repayment of Debt (TTM)

-$48.92M